Business
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth qu
About this update from Nasus Pharma Ltd.
[{"type":"image","alt":"Nasus Pharma, Ltd.","displaySize":"","headline":null,"caption":"Nasus Pharma, Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":241,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/quoV9o_G7y0qGuyE83dEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d","width":241,"height":136}},"lazy":false},{"type":"text","content":"NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen®","length":280,"tagName":"p"},{"type":"text","content":"NS002 continued to demonstrate a favorable safety profile with no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants","length":172,"tagName":"p"},{"type":"text","content":"Pivotal study initiation planned for fourth quarter of 2026","length":59,"tagName":"p"},{"type":"text","content":"Conference call and webcast scheduled for 8:00 a.m. EDT today","length":61,"tagName":"p"},{"type":"text","content":"TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive top line results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The comprehensive analysis demonstrated that NS002 achieved significantly faster and higher early epinephrine absorption compared to intramuscular EpiPen® autoinjector. The Company plans to initiate its pivotal clinical study in fourth quarter of 2026.","length":687,"tagName":"p"},{"type":"text","content":"The open-label Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis. All subjects received a single and repeat dose of NS002 and intramuscular EpiPen® with and without a nasal allergic challenge (“NAC”). This robust study design provided comprehensive data supporting NS002's c...